Skip to content
drillr.ai
Sign up

LEXX

Lexaria Bioscience Corp.

NASDAQ · Healthcare · Biotechnology · CA

$3.19
−3.04%
Ask drillr

  • Sep 18, 2026, 01:45 UTC

    Lexaria Bioscience Corp. completed an institutional financing that, together with an Australian tax refund, brought in a net $7.9 million.

    Source:

  • Sep 8, 2026, 12:00 UTC

    Lexaria Bioscience Corp. announced definitive agreements for the immediate exercise of outstanding warrants to purchase 453,969 shares of common stock at a reduced exercise price of $12.92 per share, expecting gross proceeds of approximately $5.9 million, with closing expected on or about September 9, 2026.

    Source:

  • Sep 1, 2026, 13:15 UTC

    Lexaria Bioscience Corp. received a cash rebate of AUD$3,666,611.98 (USD$2.6 million) from the Australian Tax Office, deposited into the account of its wholly-owned subsidiary Lexaria (AU) Pty Ltd.

    Source:

  • Aug 24, 2026, 13:10 UTC

    Lexaria Bioscience announced completion of pharmacokinetic bioanalysis testing in its 2026 Animal Study #2, which evaluated oral delivery of amycretin and retatrutide using its DehydraTECH platform, showing significant absorption improvements.

    Source:

  • Aug 13, 2026, 13:00 UTC

    Lexaria Bioscience Corp. entered into a Material Transfer Agreement with PegBio Co., Ltd to investigate Lexaria's DehydraTECH technology with a PegBio molecule under development for the GLP-1 industry.

    Source:

  • Jun 25, 2026, 13:10 UTC

    Lexaria Bioscience Corp. began dosing on schedule on June 14, 2026, for its Human Pilot Study #7 (GLP-1-H26-7) evaluating two oral DehydraTECH-semaglutide compositions against Novo Nordisk's Wegovy tablets.

  • Jun 23, 2026, 13:25 UTC

    Lexaria Bioscience Corp. began dosing in its Animal Study #1 (GLP-1-A26-1) evaluating DehydraTECH-semaglutide and DehydraTECH-CBD compositions.

    Source: